MANNKIND CORP
MannKind is a biopharmaceutical company focused on treatments for cardiometabolic and orphan lung diseases, including diabetes, pulmonary hypertension and fluid overload associated with heart failure and chronic kidney disease. Its cardiometabolic products are Afrezza, an inhaled insulin; Furoscix, a subcutaneous furosemide treatment; and V-Go, a wearable insulin delivery device. MannKind commercializes these products in the United States and works with regional partners outside the country. It also develops inhaled treatments for orphan lung diseases. United Therapeutics commercializes Tyvaso DPI and pays MannKind royalties on net sales, while MannKind manufactures and supplies the product and receives supply payments. Its pipeline includes MNKD-201 for idiopathic pulmonary fibrosis and MNKD-701, an inhaled bumetanide program. MannKind develops and manufactures Technosphere powders and inhalers at its facility in Danbury, Connecticut, where it is headquartered.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $MNKD in the last 7 days.
No SEC Form 4 filings for $MNKD in the last 30 days.
See all $MNKD insider activity →RBC Capital maintained its Sector Perform rating on MannKind but raised its price target to $5 from $4.75, suggesting a 33% upside from the Nov 5 close of $3.76. Recent analyst notes on MannKind have price targets ranging from $5 to $10.
MannKind (MNKD) reported Q3 2026 revenue of $101.9M, up 24% YoY. Furoscix ReadyFlow approval drove strong adoption, with 75% of prescriptions converted. Afrezza pediatric launch exceeded forecasts, with total prescriptions up 17% sequentially. The company anticipates $15M in milestones from ralinepag DPI in 2027 and key clinical data for nintedanib DPI in early 2028. MannKind closed a $50M private placement, funding a $45M CVR payment.
Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.
Recent MNKD coverage spans financial news and earnings.
The note is a bullish valuation adjustment that can support near-term sentiment, but it is not a new company fundamental catalyst.
Earnings beat revenue expectations and highlighted strong Furoscix growth.
Analyst upgrade with a higher price target suggests potential upside for MNKD.
The guidance suggests a material revenue boost and a path to profitability, likely supporting the stock.
Earnings beat revenue expectations but loss and modest guidance may weigh on the stock.
AlphAI scores every news story that mentions MNKD with an AI model for sentiment and relevance, and aggregates insider trades from MANNKIND CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
RBC Capital maintained its Sector Perform rating on MannKind but raised its price target to $5 from $4.75, suggesting a 33% upside from the Nov 5 close of $3.76. Recent analyst notes on MannKind have price targets ranging from $5 to $10.
MannKind (MNKD) reported Q3 2026 revenue of $101.9M, up 24% YoY. Furoscix ReadyFlow approval drove strong adoption, with 75% of prescriptions converted. Afrezza pediatric launch exceeded forecasts, with total prescriptions up 17% sequentially. The company anticipates $15M in milestones from ralinepag DPI in 2027 and key clinical data for nintedanib DPI in early 2028. MannKind closed a $50M private placement, funding a $45M CVR payment.
Cantor Fitzgerald raised its price target for MannKind Corp. (NASDAQ:MNKD) to $10.00, citing momentum for Tyvaso DPI and a delayed competitor. The firm expects profitability in 2026, with revenue growth of 30% and a 75% gross margin. MannKind reported Q3 2026 revenue of $101.9M, missing estimates but showing a smaller loss than expected. The company's commercial products and royalties drove growth.
MannKind (MNKD) expects $1B in revenue from its United Therapeutics deal between 2027-2030. The company aims for profitability in Q4 2026, driven by record revenue. CEO Michael Castagna emphasized executing on catalysts. (Source: Seeking Alpha)
MannKind (MNKD) reported Q3 2026 earnings, with FUROSCIX revenue expected to reach $38M in Q4. Afrezza revenue rose 5% YoY to $19.3M, driven by pediatric prescriptions. Total revenue increased 27% YoY to $301.4M, but net loss was $58.9M. The company plans to expand its sales force and focus on adult Afrezza business. Pipeline updates include a 2028 data readout for INFLO-2 and $15M milestones from ralinepag DPI program with United Therapeutics.
MANNKIND CORP (MNKD) filed an SEC Form 8-K — Results of Operations and Financial Condition. MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update • Q3 2026 total revenues of $101.9 million, +24% vs. Q3 2025 • Q3 2026 commercial product revenue of $45.0 million, +102% vs. Q3 2025 o Furoscix ReadyFlow ™ was approved and shipments commenced mid
MannKind (MNKD) will release Q3 2026 earnings after market close on Nov. 5, followed by a conference call at 4:30 p.m. ET. The call will discuss financial results and provide a business update. The webcast will be available on the company's Investor Relations website.
MannKind (MNKD) advances inhaled IPF drug to global Phase 2, with potential human testing by year-end. CEO Castagna highlights FUROSCIX's strong adoption, shifting sales focus to nephrology. Company reports sufficient cash for growth, aiming for profitability next year. Vicore Pharma's Phase 2b study for IPF treatment expected to report results in summer 2025.
Cantor Fitzgerald maintained an Overweight rating on MannKind with an $8 price target, suggesting a 158.9% upside from the Oct 19 close of $3.09. The firm cited MannKind's strong product pipeline and positive market response to recent product launches.
Chardan Capital initiated coverage of MannKind with a Buy rating and $10 price target, implying a 228.9% upside from the Oct 16 close. The analyst highlights MannKind's strong pipeline, including Furoscix, Afrezza, and MNKD-201, and positive market dynamics for these products.
